Related Experiment Video
Updated: Jan 21, 2026

Antibiotic Dereplication Using the Antibiotic Resistance Platform
Published on: October 17, 2019
An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic
Steven Opal1, Thomas M File2,3, Tom van der Poll4,5
1Warren Alpert Medical School of Brown University, Providence, Rhode Island.
Abstract:
Omadacycline is a semisynthetic tetracycline antibiotic. Phase III clinical trial results have shown that omadacycline has an acceptable safety profile in the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. Similar to most tetracyclines, transient nausea and vomiting and low-magnitude increases in liver aminotransferases were the most frequent treatment-emergent adverse events in phase III studies but were not treatment limiting. Package insert warnings and precautions for omadacycline include tooth discoloration; enamel hypoplasia; inhibition of bone growth following use in late pregnancy, infancy, or childhood up to 8 years of age; an imbalance in mortality (2%, compared with 1% in moxifloxacin-treated patients) was observed in the phase III study in patients with community-acquired bacterial pneumonia. Omadacycline has no effect on the QT interval, and its affinity for muscarinic M2 receptors resulted in transient heart rate increases following dosing.
Insights
Omadacycline, a novel tetracycline antibiotic, demonstrates an acceptable safety profile for treating skin infections and pneumonia. Common side effects like nausea were generally not limiting, though specific warnings apply to pediatric use and pregnancy.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Trials
Background:
- Omadacycline is a novel, semisynthetic tetracycline antibiotic.
- Tetracyclines are a class of broad-spectrum antibiotics used to treat various bacterial infections.
Purpose of the Study:
- To evaluate the safety and tolerability of omadacycline in Phase III clinical trials.
- To assess the efficacy of omadacycline in treating acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
Main Methods:
- Phase III clinical trials were conducted to assess omadacycline's safety and efficacy.
- Adverse events, laboratory changes, and specific warnings were documented during the trials.
Main Results:
- Omadacycline exhibited an acceptable safety profile in patients with ABSSSI and CABP.
- The most frequent adverse events were transient nausea, vomiting, and minor increases in liver aminotransferases, which were not treatment-limiting.
- Specific warnings include potential tooth discoloration, enamel hypoplasia, and inhibition of bone growth in young children and during pregnancy. An imbalance in mortality was observed in the CABP study.
Conclusions:
- Omadacycline is a potentially valuable therapeutic option for ABSSSI and CABP, with a generally manageable safety profile.
- Healthcare providers must carefully consider the established warnings and precautions, particularly regarding use in pediatric populations and pregnant women.
More Related Videos
Related Concept Videos
5-Number Summary
In a box plot, the minimum and maximum data values represent the lower and upper whiskers in the graph, and the median is designated as the center of the box in the chart. The first quartile and third...
Discharge Summary Forms
Here's a detailed look at the key components and guidelines for preparing a discharge summary:
Antibiotic Selection
Survey Safety
Household Wiring And Electrical Safety
Development of Antibiotic Resistance

